Accuri C6 Flow Cytometer System
Originally published online as doi:10.1189/jlb.0809590 on December 9, 2009

Published online before print December 9, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Buy
Right arrow All Versions of this Article:
jlb.0809590v1
87/2/223    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by del Rio, M. L.
Right arrow Articles by Rodriguez-Barbosa, J. I.
PubMed
Right arrow PubMed Citation
Right arrow Articles by del Rio, M. L.
Right arrow Articles by Rodriguez-Barbosa, J. I.
(Journal of Leukocyte Biology. 2010;87:223-235.)
© 2010 Society for Leukocyte Biology

HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation

M. L. del Rio*, C. L. Lucas{dagger}, L. Buhler{dagger},{ddagger}, G. Rayat§ and J. I. Rodriguez-Barbosa*,1

* Laboratory of Immunobiology, Institute of Biomedicine, Campus de Vegazana s/n, Leon, Spain;
{dagger} Bone Marrow Transplantation Section, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA;
{ddagger} Surgical Research Unit, Department of Surgery, University Hospital Geneva, Geneva, Switzerland; and
§ Alberta Diabetes Institute, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada

1. Correspondence: Institute of Biomedicine (Immunobiology), University of Leon, Campus de Vegazana s/n, 24071-Leon, Spain. E-mail: ignacio.barbosa{at}unileon.es

Abstract

Immunosuppression is currently the treatment of choice to attenuate the chronic deterioration of tissue function as a result of the effector mechanisms of the immunological response in transplant rejection and autoimmune diseases. However, global immunosuppression greatly increases the risk of acquiring life-threatening infections and is associated with organ toxicity when used long-term. Thus, alternative approaches that inhibit only the unwanted immune responses and preserve general immunity are highly desirable. The receptor/ligand pairs involved in the cross-talk between DC and T cells have been the focus of intense and exciting research during the last decade. The HVEM/LIGHT/BTLA/CD160 costimulatory/coinhibitory pathway has emerged as a potential target for the development of immune therapeutic interventions. Herein, we will summarize and discuss how blockade of the costimulatory HVEM/LIGHT interaction or agonist signaling through the inhibitory BTLA and CD160 receptors could contribute to the control of deleterious immune responses.

Key Words: coinhibition • costimulation • transplantation • autoimmunity